Identity
- Security key
- 14893
- Ticker
- ERAS
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2021-07-16
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- ERAS
Detail
Enriched 2026-08-14 20:47
- Market cap
- $6,498,578,610.3
- Shares outstanding (class)
- 310,984,542
- Shares outstanding (weighted)
- 349,762,035
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 103
- Location
- SAN DIEGO, CA
- Homepage
- https://www.erasca.com
- Description
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
Market cap and share counts drift.